XBiotech To Provide Third Quarter 2016 Business Update On November 15

AUSTIN, Texas, Nov. 10, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of True Human™ therapeutic antibodies, announced today that it will host a live conference call and webcast on Tuesday, November 15, 2016, at 8:30 a.m. ET, to provide a quarterly overview for the third quarter ended September 30, 2016.

Conference Call Information: Interested participants and investors may access the conference call by dialing:
  • 1 (844) 249-9385 (U.S.)
  • 1 (270) 823-1533 (international)
  • Conference ID: 13324077

A webcast will also be accessible via the Investors Relations section of the XBiotech website investors.xbiotech.com. The webcast replay will remain available for 90 days.

About True Human™ Therapeutic AntibodiesUnlike previous generations of antibody therapies, XBiotech's True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability.

About XBiotech XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

If you liked this article you might like

Alexion Pops, Biogen Falls on Executive Shuffle; Epizyme Recovers As Investors Digest Phase 2 Data

Biotech Movers: Coherus, XBiotech, Flexion

Biotech Movers: Minerva, XBiotech, Aduro

Biotech Movers: Lion Biotechnologies, XBiotech, Halozyme

XBiotech No. 2 Executive Resigns, Leaving Struggling Biotech Without Top Operations Chief